300750 CONTEMPORARY AMPEREX TECHNOLOGY CO

EQS-News: Dr. Björn Beckmann Appointed Head of Quality Control at Rentschler Biopharma’s Laupheim Site

EQS-News: Rentschler Biopharma SE / Key word(s): Personnel
Dr. Björn Beckmann Appointed Head of Quality Control at Rentschler Biopharma’s Laupheim Site

31.10.2023 / 10:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Dr. Björn Beckmann Appointed Head of Quality Control at Rentschler Biopharma’s Laupheim Site

Laupheim, Germany, October 31, 2023 – Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced that Dr. Björn Beckmann has been promoted to Head of Quality Control for the Company’s site in Laupheim, Germany, effective October 1, 2023. In this new role, he is responsible for all aspects of quality control (QC), including for the development, production, release and approval of active pharmaceutical ingredients and therapeutics, and for ensuring that all quality standards and regulations are met. He also oversees the teams responsible for developing quality management strategies and preparing quality control audits by authorities and clients. In this role, he reports to Laupheim’s Site Head.

Christiane Bardroff, Chief Operating Officer, said: “Björn has taken on increasing responsibility in his seven years at Rentschler Biopharma and has distinguished himself through his strong commitment and outstanding performance. He particularly impressed with his outstanding leadership qualities and the ability to develop and implement innovative solutions with the team. Björn is thus the perfect choice to lead the quality control and ensure that our complex and customized products continue to meet the highest standards to the full satisfaction of our clients, and thus improve the lives of patients sustainably. I am very pleased that we have been able to fill this senior position internally. This underlines that we qualify our employees sustainably and are developing them into leaders."

Dr. Beckmann has been with Rentschler Biopharma for seven years and has been promoted to positions of higher responsibility during this period. Most recently, he served as Senior Director Production Support, leading a team of approximately 150 employees in various areas, including buffer and media production, manufacturing compliance, DSP major equipment/process preparation, cleanroom maintenance, and small equipment preparation. In this role, he contributed to the improvement and advancement of all production supporting functions and was a member of the Site Leadership Team as a representative of the production. Dr. Beckmann received a PhD in technical chemistry from Leibniz Universität Hannover and an MS in pharmaceutical biotechnology from the University of Applied Sciences in Hamburg.

"Since joining Rentschler Biopharma, I have had the opportunity to grow with the company and be part of its remarkable journey. I am pleased to take on the role of Head of Quality Control in Laupheim, and I am grateful for the trust that both management and Site Head have placed in me. Achieving the highest quality isn't a matter of chance but the result of persistent effort, and it is a top priority here at Rentschler Biopharma. I am extremely proud to be a part of this global, dedicated team and look forward to working together with our partners to not only meet but exceed expectations," commented Dr. Björn Beckmann, Head of Quality Control.
 

About Rentschler Biopharma SE

Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals, including adeno-associated virus (AAV) gene therapies, as well as related consulting activities, project management and regulatory support. Rentschler Biopharma's high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. Rentschler Biopharma is a family-owned company with about 1,200 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. Rentschler ATMP Ltd., located in Stevenage, UK, is dedicated to cell and gene therapies.

For further information, please visit . Follow Rentschler Biopharma on and .
 

Contact:

Rentschler Biopharma SE

Dr. Latika Bhonsle-Deeng
Senior Director Corporate Communication
Phone: 4

Media inquiries:

MC Services AG
Eva Bauer
Phone:
U.S.
Laurie Doyle
Phone:


For high-resolution images, please contact .



31.10.2023 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at -news.com


1759623  31.10.2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1759623&application_name=news&site_id=research_pool
EN
31/10/2023

Underlying

300750CONTEMPORARY AMPEREX TECHNOLOGY CO

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on CONTEMPORARY AMPEREX TECHNOLOGY CO

 PRESS RELEASE

EQS-News: vbw Pressemitteilung zum Koalitionsvertrag: Gute Grundlage

Emittent / Herausgeber: ibw – Informationszentrale der Bayerischen Wirtschaft e. V. / Schlagwort(e): Sonstiges/Sonstiges vbw Pressemitteilung zum Koalitionsvertrag: Gute Grundlage 10.04.2025 / 09:30 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. vbw zum Koalitionsvertrag: Gute Grundlage Brossardt: „Koalitionsvertrag schafft Planungssicherheit und setzt Wachstumsimpulse“  Bertram Brossardt, Hauptgeschäftsführer der vbw – Vereinigung der Bayerischen Wirtschaft e. V.: (München, 09.04.2025). Wir freuen uns, dass jetzt der Weg frei ist f...

 PRESS RELEASE

Aquis Stock Exchange - suspension of trading

Aquis Stock Exchange Aquis Stock Exchange - suspension of trading 10-Apr-2025 / 07:00 GMT/BST The issuer is solely responsible for the content of this announcement. The following securities are suspended from trading on the Aquis Growth Market from 08.00, 10 April 2025, at the request of the company: Richmond Hill Resources Plc Ordinary Shares Symbol: SHNJ ISIN: GB00BNTBWF32 The Regulation Department Aquis Stock Exchange Floor 2, 63 Queen Victoria Street, EC4N 4UA Tel: 0203 597 6361 Email:  Website:  Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The i...

 PRESS RELEASE

EQS-News: CO2Coin one of the most successful crypto investments of the...

Issuer: Clima4Future Ltd. / Key word(s): Cryptocurrency / Blockchain/Market Launch CO2Coin one of the most successful crypto investments of the coming decades. 10.04.2025 / 04:55 CET/CEST The issuer is solely responsible for the content of this announcement.     CO2Coin is going through a phase of phenomenal growth. A year ago the price was just €1, today it is around 270 USDT - an increase in value that illustrates the enormous potential of this unique project. This development reflects the crypto community's growing interest in sustainable investments. Clima4Future Lt...

 PRESS RELEASE

EQS-News: CO2Coin eine der erfolgreichsten Krypto-Investitionen der ko...

Emittent / Herausgeber: Clima4Future Ltd. / Schlagwort(e): Kryptowährung / Blockchain/Markteinführung CO2Coin eine der erfolgreichsten Krypto-Investitionen der kommenden Jahrzehnte. 10.04.2025 / 04:55 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Der CO2Coin hat einen beeindruckenden Kursanstieg erlebt. Vor einem Jahr lag der Kurs noch bei 1 €, heute liegt er bei rund 270 USDT - eine Wertsteigerung, die das enorme Potenzial dieses einzigartigen Projekts verdeutlicht. Diese Entwicklung spiegelt das wachsende Interesse der Krypto-Com...

 PRESS RELEASE

EQS-News: Zimbabwe Government Delivers on Commitment: Compensation of ...

EQS-News: Zimbabwe Ministry of Finance, Economic Development and Investment Promotion / Key word(s): Miscellaneous Zimbabwe Government Delivers on Commitment: Compensation of Former Farm Owners under the Global Compensation Deed Commences 09.04.2025 / 20:20 CET/CEST The issuer is solely responsible for the content of this announcement. In line with the GCD agreement, the FFOs receive 1 per cent of their claim in cash, with the balance being paid through US$ denominated Treasury bonds with a 2 per cent coupon and maturities of 2 to 10 years HARARE, Zimbabwe, April 9, 2025...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch